Recent studies have identified autoantibodies against fibroblast growth factor receptor 3 (FGFR3) as a potential biomarker for sensory neuropathies particularly affecting the dorsal root ganglia (DRG), such as sensory neuronopathy (SNN) and small fiber neuropathy (SFN) (3–5). The gene discussed is FGFR3; the disease is Sensory neuropathy.